ELK-003
Ocular manifestations of Epidermolysis Bullosa (EB)
Pre-clinical/Early ClinicalActive
Key Facts
Indication
Ocular manifestations of Epidermolysis Bullosa (EB)
Phase
Pre-clinical/Early Clinical
Status
Active
Company
About Eliksa Therapeutics
Eliksa Therapeutics is a private, pre-revenue biotech founded in 2018 and based in Cambridge, USA. The company is developing regenerative biologic therapies for rare diseases, with its lead program, ELK-003, targeting ocular complications in Epidermolysis Bullosa (EB), an ultra-rare genetic disorder primarily affecting children. Eliksa operates its own cGMP manufacturing facility and is backed by investors and research partnerships within the rare disease community. The company is in the pre-clinical or early clinical stage, positioning it as a specialized player in a high-need, niche market.
View full company profile